EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access

Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma

Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, Yingrui Shi, Feng Jin, Ruilian Xu, Jianji Pan, Shenhong Qu und 28 weitere

JAMA · 28.11.2023 · 330 (20) · 1961

DOI: 10.1001/jama.2023.20181 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 28.11.2023. Verfasst von Hai-Qiang Mai und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnos…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Cisplatin, Gemcitabine. Die Arbeit wurde bisher 300-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance There are currently no therapies approved by the US Food and Drug Administration for nasopharyngeal carcinoma (NPC). Gemcitabine-cisplatin is the current standard of care for the first-line treatment of recurrent or metastatic NPC (RM-NPC).

Objective

To determine whether toripalimab in combination with gemcitabine-cisplatin will significantly improve progression-free survival and overall survival as first-line treatment for RM-NPC, compared with gemcitabine-cisplatin alone. Design, Setting, and Participants JUPITER-02 is an international, multicenter, randomized, double-blind phase 3 study conducted in NPC-endemic regions, including mainland China, Taiwan, and Singapore. From November 10, 2018, to October 20, 2019, 289 patients with RM-NPC with no prior systemic chemotherapy in the RM setting were enrolled from 35 participating centers.

Interventions

Patients were randomized (1:1) to receive toripalimab (240 mg [n = 146]) or placebo (n = 143) in combination with gemcitabine-cisplatin for up to 6 cycles, followed by maintenance with toripalimab or placebo until disease progression, intolerable toxicity, or completion of 2 years of treatment. Main Outcome Progression-free survival as assessed by a blinded independent central review. Secondary end points included objective response rate, overall survival, progression-free survival assessed by investigator, duration of response, and safety.

Results

Among the 289 patients enrolled (median age, 46 [IQR, 38-53 years; 17% female), at the final progression-free survival analysis, toripalimab treatment had a significantly longer progression-free survival than placebo (median, 21.4 vs 8.2 months; HR, 0.52 [95% CI, 0.37-0.73]). With a median survival follow-up of 36.0 months, a significant improvement in overall survival was identified with toripalimab over placebo (hazard ratio [HR], 0.63 [95% CI, 0.45-0.89]; 2-sided P = .008). The median overall survival was not reached in the toripalimab group, while it was 33.7 months in the placebo group. A consistent effect on overall survival, favoring toripalimab, was found in subgroups with high and low PD-L1 (programmed death–ligand 1) expression. The incidence of all adverse events, grade 3 or greater adverse events, and fatal adverse events were similar between the 2 groups. However, adverse events leading to discontinuation of toripalimab or placebo (11.6% vs 4.9%), immune-related adverse events (54.1% vs 21.7%), and grade 3 or greater immune-related adverse events (9.6% vs 1.4%) were more frequent in the toripalimab group. Conclusions and Relevance The addition of toripalimab to chemotherapy as first-line treatment for RM-NPC provided statistically significant and clinically meaningful progression-free survival and overall survival benefits compared with chemotherapy alone, with a manageable safety profile. These findings support the use of toripalimab plus gemcitabine-cisplatin as the new standard of care for this patient population. Trial Registration ClinicalTrials.gov Identifier: NCT03581786

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsCisplatinGemcitabineNasopharyngeal CarcinomaNasopharyngeal NeoplasmsAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodNeoplasm Recurrence, LocalUnited StatesInternationality

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsCisplatinGemcitabinetoripalimab

Autor:innen und Institutionen

  • Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou.
  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
  • Fudan University Cancer Center, Shanghai, China.
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China.
  • Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
  • Jiangxi Cancer Hospital, Nanchang, China.

Zitieren

APA

Mai, H. Q., Chen, Q. Y., Chen, D., Hu, C., Yang, K., Wen, J., Li, J., Shi, Y., Jin, F., Xu, R., Pan, J., Qu, S., Li, P., Hu, C., Liu, Y. C., Jiang, Y., He, X., Wang, H. M., Lim, W. T., …, & Xu, R. H. (2023). Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma. JAMA, 330(20), 1961. https://doi.org/10.1001/jama.2023.20181

Vancouver

Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma. JAMA. 2023;330(20):1961. doi:10.1001/jama.2023.20181

BibTeX
@article{Mai2023,
  author = {Mai, Hai-Qiang and Chen, Qiu-Yan and Chen, Dongping and Hu, Chaosu and Yang, Kunyu and Wen, Jiyu and Li, Jingao and Shi, Yingrui and Jin, Feng and Xu, Ruilian and Pan, Jianji and Qu, Shenhong and Li, Ping and Hu, Chunhong and Liu, Yi-Chun and Jiang, Yi and He, Xia and Wang, Hung-Ming and Lim, Wan-Teck and Liao, Wangjun and He, Xiaohui and Chen, Xiaozhong and Wang, Siyang and Yuan, Xianglin and Li, Qi and Lin, Xiaoyan and Jing, Shanghua and Chen, Yanju and Lu, Yin and Hsieh, Ching-Yun and Yang, Muh-Hwa and Yen, Chia-Jui and Samol, Jens and Luo, Xianming and Wang, Xiaojun and Tang, Xiongwen and Feng, Hui and Yao, Sheng and Keegan, Patricia and Xu, Rui-Hua},
  title = {Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma},
  journal = {JAMA},
  year = {2023},
  volume = {330},
  number = {20},
  pages = {1961},
  doi = {10.1001/jama.2023.20181}
}
Kostenlos starten →